Journal of Hepatology
Volume 47, Issue 4 , Pages 441-443 , October 2007

Treatment of chronic HCV in advanced liver disease: Unmet challenges, reason for optimism

References 

  1. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485–1492
  2. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  3. Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–965
  5. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673–1680
  6. Everson G, Hoefs J, Seeff L, Bonkovsky H, Naishadham D, Shiffman M, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology. 2006;44:1675–1684
  7. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303–1313
  8. Cammà C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros S, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology. 2004;39:333–342
  9. Wright T. Treatment of patients with hepatitis C and cirrhosis. Hepatology. 2002;36:S185–S194
  10. Veldt BJ, Saracco G, Boyer N, Cammà C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut. 2004;53:1504–1508
  11. Coverdale SA, Khan MH, Byth K, Lin R, Weltman M, George J, et al. Effects ofinterferon treatment response on liver complications of chronic hepatitis C: 9-year follow up study. Am J Gastroenterol. 2004;99:636–644
  12. International Interferon–International Interferon-α Hepatocellular Carcinoma Study Group. Effect of interferon-α on progression of cirrhosis to hepatocellularcarcinoma: a retrospective cohort study. Lancet 1998;351:1535–1539.
  13. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–587
  14. Di Marco V, Almasio PL, Ferraro D, Calvaruso V, Alaimo G, Peralta S, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: A randomized controlled trial. J Hepatol. 2007;47:484–491
  15. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C 2002. Hepatology 2002;36:S3–S20.
  16. Everson GT, Trotter JF, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42:255–262
  17. Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol. 2003;98:2491–2499

☆ The authors declare that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

PII: S0168-8278(07)00405-9

doi: 10.1016/j.jhep.2007.07.009

Journal of Hepatology
Volume 47, Issue 4 , Pages 441-443 , October 2007

Article Tools